Brief: Hepion Pharmaceuticals Announces Passing Of Key Safety Milestone In Phase 2B Trial Of Rencofilstat
15/06/2023 14:28
June 15 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS ANNOUNCES PASSING OF KEY SAFETY
MILESTONE
IN PHASE 2B ‘ASCEND-NASH’ TRIAL OF RENCOFILSTAT
* HEPION PHARMACEUTICALS INC - ON TRACK TO COMPLETE
ENROLLMENT IN
ASCEND-NASH IN Q1 OF 2024
Source text for Eikon: ID:nGNX76YhTN
Further company coverage: HEPA.O
(reuters.briefs@thomsonreuters.com)
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement